[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100578626":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":54,"collaborators":10,"id":56,"slug":10,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":10,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":10,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":10,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"First Affiliated Hospital of Zhejiang University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"18F-MFBG PET\u002FCT in Pheochromocytoma",null,"Each patient receive a single intravenous injection of 18F-MFBG 5.55 MBq\u002Fkg and undergo PET\u002FCT or PET\u002FMR scan after 60 min post-injection.",[13],"Drug: 18F-MFBG",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","18F-MFBG","Patients with pheochromocytoma malignancies receive 5.55 MBq\u002Fkg of 18F-MFBG intravenously followed by PET\u002FCT or PET\u002FMR after 60min of injection.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Peipei Wang, MD","CONTACT","86 18511395988","wpp199411@163.com",[27,45],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"The First Affiliated Hospital of Zhejiang University School of Medicine","RECRUITING","Hangzhou","Zhejiang","310003","China",{"type":35,"coordinates":36},"Point",[37,38],120.16142,30.29365,{"lat":38,"lon":37},[41],{"name":42,"role":23,"phone":43,"phoneExt":10,"email":44},"Xinhui Su, MD","86 13806071262","suxinhui@zju.edu.cn",{"facility":46,"status":29,"city":30,"state":31,"zip":47,"country":33,"cosmosGeoPoint":48,"geoPoint":50,"contacts":51},"The First Affiliated Hospital Zhejiang University School of Medicine","310006",{"type":35,"coordinates":49},[37,38],{"lat":38,"lon":37},[52,53],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},{"name":42,"role":23,"phone":43,"phoneExt":10,"email":44},{"type":55,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100578626",false,"NCT06813742","18F-mFBG PET Imaging in the Evaluation of Pheochromocytoma","A Prospective Exploratory Study Evaluating the Diagnostic Usefulness of 18F-mFBG PET Imaging in Pheochromocytoma","Inclusion Criteria:\n\n1. Aged 30-80 years old, primary school or above, with a regular caregiver;\n2. Clinically diagnosed patients with pheochromocytoma;\n3. Can provide informed consent, can understand and comply with the study requirements.\n\nExclusion Criteria:\n\n1. Patients with serious primary diseases such as heart, brain, liver, kidney and hematopoietic system;\n2. Uncontrolled hypertension or high-risk BP (i.e., systolic BP \\> 180 mmHg or diastolic BP \\> 110 mmHg);\n3. Patients with mental disorders or primary affective disorders;\n4. Unable to understand and adhere to the study protocol or provide informed consent;\n5. Contraindications to PET imaging (including pregnant women, lactating women, and women of childbearing age with recent childbearing plans, etc.);\n6. Allergy to imaging agents;\n7. Patients who were unable to cooperate with PET scanning, such as hypoglycemia, severe pain or tremor.","ALL","18 Years","80 Years",{"count":66,"type":67},80,"ESTIMATED","OBSERVATIONAL","The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with pheochromocytoma.",[71],"Pheochromocytoma","2025-08-06",{"date":74,"type":75},"2025-08-07","ACTUAL",{"date":77,"type":75},"2023-05-01",{"date":79,"type":67},"2026-12",{"name":5,"class":6},2]